1281816-04-3 Usage
Uses
Used in Anticancer Applications:
N2'-deacetyl-N2'-[3-[[1-[[4-[[[(1S)-5-amino-1-carboxypentyl]amino]carbonyl]cyclohexyl]methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]maytansine is used as an anticancer agent for the targeted eradication of cancer cells that express specific antigens on their cell surface. Its unique structure allows for selective binding and internalization by cancer cells, leading to the inhibition of cell growth and induction of apoptosis.
Used in Drug Delivery Systems:
In the pharmaceutical industry, N2'-deacetyl-N2'-[3-[[1-[[4-[[[(1S)-5-amino-1-carboxypentyl]amino]carbonyl]cyclohexyl]methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]maytansine is utilized in the development of drug delivery systems to improve the efficacy and safety of cancer treatments. Its targeted nature enables the design of conjugates with monoclonal antibodies or other targeting moieties, allowing for precise delivery to tumor sites and minimizing damage to healthy tissues.
Used in Cancer Research:
In the field of cancer research, N2'-deacetyl-N2'-[3-[[1-[[4-[[[(1S)-5-amino-1-carboxypentyl]amino]carbonyl]cyclohexyl]methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]maytansine serves as a valuable tool for studying the mechanisms of cancer cell growth, survival, and resistance to therapy. Its potent cytotoxic effects and specific targeting properties make it an ideal candidate for investigating novel therapeutic strategies and understanding the molecular underpinnings of cancer progression.
Overall, N2'-deacetyl-N2'-[3-[[1-[[4-[[[(1S)-5-amino-1-carboxypentyl]amino]carbonyl]cyclohexyl]methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]maytansine is a promising compound with significant potential in the field of oncology, offering targeted cancer treatment options and contributing to the advancement of cancer research.
Check Digit Verification of cas no
The CAS Registry Mumber 1281816-04-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,8,1,8,1 and 6 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1281816-04:
(9*1)+(8*2)+(7*8)+(6*1)+(5*8)+(4*1)+(3*6)+(2*0)+(1*4)=153
153 % 10 = 3
So 1281816-04-3 is a valid CAS Registry Number.
1281816-04-3Relevant academic research and scientific papers
Widdison, Wayne,Wilhelm, Sharon,Veale, Karen,Costoplus, Juliet,Jones, Gregory,Audette, Charlene,Leece, Barbara,Bartle, Laura,Kovtun, Yelena,Chari, Ravi
, p. 1762 - 1773 (2015)
Several antibody-maytansinoid conjugates (AMCs) are in clinical trials for the treatment of various cancers. Each of these conjugates can be metabolized by tumor cells to give cytotoxic maytansinoid metabolites that can kill targeted cells. In preclinical
COMPOUNDS AND METHODS FOR THE TREATMENT OF EGFR POSITIVE DISEASES
-
, (2014/07/08)
Disclosed herein are anti-EGFR antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat EGFR positive cells in cancers are provided.
COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES
-
, (2014/07/08)
Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.
MAYTANSINOID DERIVATIVES
-
, (2014/07/08)
Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.
